Skip to main content

Table 1 Baseline patient, disease and prior treatment characteristics

From: Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Characteristics N = 41
Median Age (Range) 58 (33–82)
Gender Male: 29 (71%)
Female: 12 (29%)
ECOG PS 0: 15 (40%)
1: 18 (47%)
2: 5 (13%)
Unknown: 3
Race Caucasian: 27 (68%)
African American: 10 (25%)
Hispanic: 3 (7%)
Unknown: 1
Histology Papillary: 16 (39%)
Unclassified: 14 (34%)
Chromophobe: 5 (12%)
Collecting Duct: 4 (10%)
Translocation: 1 (2%)
Mucinous Tubular and Spindle Cell Carcinoma (MTSCC): 1 (2%)
Risk Group MSKCC Criteria [15]
 Favorable: 8 (21%)
 Intermediate: 25 (64%)
 Poor: 6 (15%)
 Unknown: 2
IMDC Criteria [16]
 Favorable: 10 (27%)
 Intermediate: 23 (62%)
 Poor: 4 (11%)
 Unknown: 4
Location of Metastases
(more than 1 possible)
Retroperitoneal LNs: 26 (63%)
Lung: 22 (54%)
Liver: 15 (37%)
Bone: 11 (27%)
Mediastinal LNs: 11 (27%)
Supraclavicular LNs: 7 (17%)
Mesenteric LNs: 5 (12%)
Pelvic Mass: 4 (10%)
Adrenal: 4 (10%)
Omentum: 3 (7%)
Pancreas, brain, contralateral kidney, soft tissue: 2 each (5%)
Spleen, diaphragm, gallbladder, iliac LNs: 1 each (2%)
Prior Nephrectomy 29 (73%)
Number of Prior Systemic Therapies 0: 3 (8%)
1: 25 (62%)
2: 8 (20%)
3 or more: 4 (10%)
Unknown: 1
Prior Therapies
(more than 1 possible)
Sunitinib: 26 (63%)
Pazopanib: 11 (27%)
Axitinib: 4 (10%)
Everolimus: 4 (10%)
Cabozantinib: 3 (7%)
Gemcitabine/Cisplatin: 3 (7%)
Carboplatin/Taxol: 1 (2%)
Sorafenib: 1 (2%)
Bevacizumab/Everolimus: 1 (2%)
Prior Immunotherapy Atezolizumab on trial: 1 (2%)
Ipi/Nivo trial and J14186 HAR vaccine trial: 1 (2%)
  1. In some categories percentages do not add up to 100% due to rounding
  2. Abbreviations: ECOG PS Eastern Cooperative Oncology Group Performance Status, MSKCC Memorial Sloan Kettering Cancer Center, IMDC International Metastatic Renal Cell Carcinoma Database Consortium, LNs Lymph Nodes